Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 4,370,000 shares, a growth of 6.1% from the November 30th total of 4,120,000 shares. Based on an average daily volume of 424,600 shares, the short-interest ratio is currently 10.3 days. Currently, 12.2% of the company's stock are sold short.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the transaction, the director now directly owns 31,471 shares of the company's stock, valued at $1,535,784.80. The trade was a 13.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 7,426 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company's stock, valued at approximately $4,898,061.15. This represents a 7.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,533 shares of company stock valued at $1,987,482. Corporate insiders own 27.10% of the company's stock.
Several hedge funds have recently made changes to their positions in the company. World Investment Advisors LLC bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth $1,614,000. Sanctuary Advisors LLC boosted its position in Amphastar Pharmaceuticals by 8.5% during the third quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company's stock worth $466,000 after purchasing an additional 801 shares during the period. Invst LLC increased its stake in shares of Amphastar Pharmaceuticals by 23.6% in the third quarter. Invst LLC now owns 14,390 shares of the company's stock worth $698,000 after purchasing an additional 2,752 shares in the last quarter. Hohimer Wealth Management LLC bought a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $339,000. Finally, Geode Capital Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock valued at $44,674,000 after buying an additional 14,015 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.
A number of analysts recently commented on the company. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price target for the company. StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $60.33.
View Our Latest Stock Analysis on AMPH
NASDAQ:AMPH opened at $37.13 on Wednesday. Amphastar Pharmaceuticals has a 12 month low of $36.48 and a 12 month high of $65.92. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm's 50 day moving average is $44.75 and its 200 day moving average is $44.43. The stock has a market capitalization of $1.79 billion, a PE ratio of 12.38, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78.
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.